TRAILBLAZER-REAL US: A Patient-Centered Study
For patients with mild cognitive impairment, Dementia or Alzheimer's Disease and their care partners. Care partners will be compensated for their time.
Welcome
The TRAILBLAZER-REAL US (TB-REAL) study aims to gather information about the journey of patients with early-stage Alzheimer's Disease (AD) or mild cognitive impairment, and the impact of donanemab, a medicine approved by the Food and Drug Administration (FDA) in 2024. The information gathered from this study will help improve the care for people with AD now and in the future.
The TRAILBLAZER-REAL Study Will:
Collect & Link
Longitudinal data from diverse patients with AD who are undergoing evaluation for amyloid-targeting therapies or are being treated with donanemab
Monitor
Disease progression, treatment outcomes, effectiveness, and safety
Involve Care Partners
The family member, friend or other person who is helping the patient with healthcare or healthcare decisions
Serve
As a platform for affiliated studies in evolving treatment areas
Benefits for Patients and Care Partners
You will be part of a community of thousands of patients and care partners who support safe and effective treatment for mild cognitive impairment, dementia and AD
You and your healthcare provider can talk about TB-REAL during your clinic visits
You will contribute scientific knowledge to help make care better for you and future generations
There is no cost to you
Care partners will be compensated for participating in 30-minute checks-ins with a study team member every six months
Benefits for Providers
TB-REAL is designed to work with healthcare provider's existing standard of care
There are no forms for healthcare providers to complete. Patients/care partners sign themselves up for TB-REAL.
Education resources and messaging are provided to support healthcare provider/patient discussions, enrollment and questions
The study is generalizable for research purposes for different types of healthcare providers and care settings
Healthcare providers may have potential publication opportunities and access to future studies
Ready to enroll?
OM1 is partnering with Lilly for this study. Clicking this link will redirect you to an OM1 enrollment page. Please see OM1's privacy policy.
See What’s Possible
Discover how OM1 delivers actionable evidence and predictive insights to transform healthcare decisions.